Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium
Sanofi India and Cipla announced an exclusive partnership for the distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range in India. As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium, a leading brand in the anti-epileptic medication category.
While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally, Cipla will leverage its capabilities and robust India-wide network of strong marketing and sales professionals, distributors, institutions, and market outreach programmes to expand access to these treatments for patients who need them.
Rodolfo Hrosz, MD, Sanofi India, said, “Sanofi India’s CNS products are leaders in their respective categories. These well-established brands already improve the lives of many patients across urban centres in the country. Cipla’s wide presence will enable us to expand the reach of this portfolio to healthcare professionals and patients across all India.”
Achin Gupta, CEO – One India Business, Cipla said, “Enhancing access to high-quality treatments is central to our purpose of ‘Caring for Life’. We are pleased to collaborate with Sanofi India to enhance accessibility to highly efficacious and quality therapeutic solutions in CNS and bring value to patients across the country. Central nervous system is one of the most challenging areas in medicine, and we believe this partnership is a significant step forward to address the unmet needs of patients.”
